FindTrial
Sign In

Exploring the formation mechanism of immune suppressive microenvironment in ccRCC based on HMGCR mediated tumor cell lipid metabolism reprogramming

Exploring the formation mechanism of immune suppressive microenvironment in ccRCC based on HMGCR mediated tumor cell lipid metabolism reprogramming

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095179
Enrollment
Unknown
Registered
2025-01-02
Start date
2025-01-06
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clear cell renal cell cancer

Interventions

ccRCC group:None
Control group:None

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Meets the diagnostic criteria for ccRCC in the 2022 edition of the European Society of Urology Kidney Cancer 2.Diagnosis and Treatment Guidelines; 3.Accept radical or partial nephrectomy treatment, and the postoperative cancer tissue is confirmed by pathological examination to be ccRCC tissue; 4.Complete clinical medical records; 4.The patient signs an informed consent form and agrees to participate in the study.

Exclusion criteria

Exclusion criteria: 1.Merge with other malignant tumors; 2.Severe abnormalities in liver and kidney function; 3.Preoperative tumor treatment such as radiotherapy and chemotherapy; 4.Suffering from severe infection.

Design outcomes

Primary

MeasureTime frame
HMGCR protein expression and mRNA levels;—

Countries

China

Contacts

Public ContactLu Tefei

Ningbo Medical Centre Lihuili Hospital

lutefei@163.com+86 574 87018592

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026